UMEM Educational Pearls - Critical Care

Drug-Induced Thrombocytopenia

  • Thrombocytopenia is common in critically ill patients and is associated with increased mortality.
  • Up to 25% of critically ill patients will develop thrombocytopenia as a result of a medication, termed drug-induced thrombocytopenia (DIT)
  • Antibiotcs are a common, yet infrequently recognized, cause of DIT.
  • Antibiotics reported to cause DIT include linezolid, vancomycin, trimethoprim/sulfamethoxazole, and the beta-lactams.
  • In fact, piperacillin/tazobactam has been associated with DIT more frequently than any other penicillin. 

Show References



Category: Critical Care

Title: ICU Acquired Weakness

Posted: 7/19/2010 by Mike Winters, MD (Emailed: 7/20/2010) (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

ICU Acquired Weakness

  • ICU acquired weakness (ICU-aw) is a general term that refers to the weakness that develops in critically ill patients during the course of their illness - especially in patients with sepsis and those receiving mechanical ventilation.
  • ICU-aw is an very common complication of critical illness that can develop within hours and has been shown to increase the duration of mechanical ventilation and ICU/hospital LOS.  Observational studies have also reported an association with mortality.
  • Risk factors associated with ICU-aw include medications (neuromuscular blocking agents, corticosteroids), hyperglycemia and immobility.
  • For the critically ill ED patient, current recommendations suggest limiting the administration of neuromuscular blocking agents and corticosteroids, when possible.

Show References



Drug-Drug Interactions in the Critically Ill

  • Critically Ill ED patients are at risk for drug-drug interactions (DDIs) due to altered organ function, polypharmacy, and altered drug kinetics.
  • DDIs involving the cytochrome isoenzyme CYP3A4 are of particular importance.
  • CYP3A4 inhibitors, such as macrolides and azoles (fluconazole, voriconazole), can cause serious DDIs when given concomitantly with meds that are a subtrate for CYP3A4 - midazolam, cyclosporine, tacrolimus, diltiazem, amiodarone.
  • Pay particular attention to your transplant patients, as administration of an azole can result in significant cyclosporine or tacrolimus toxicity.

Show References



Asthma, Peak Pressures, and the Ventilator

  • In previous pearls, we have highlighted ventilator settings for the asthmatic, along with the differences between peak and plateau pressure measurements.
  • When ventilating the asthmatic, pay attention to the ventilator settings placed by your respiratory therapist.
  • In general, the respiratory therapist will set the ventilator to stop delivering tidal volumes when the peak pressure exceeds 40-60 cm H2O.
  • For asthmatics, this practice can result in very low tidal volumes.
  • Thus, peak pressure limits must be set higher.
  • As you know, high peak pressures have not been shown to be injurious, provided that the plateau pressure remains < 30 cm H2O

Show References



Category: Critical Care

Title: Acidosis and Intubation

Posted: 6/29/2010 by Mike Winters, MD (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

Pre-existing acidosis and mechanical ventilation

  • Not surprisingly, many critically ill ED patients often develop a metabolic acidosis.
  • To compensate, patients hyperventilate, thereby producing a respiratory alkalosis.
  • When these patients require intubation and mechanical ventilation, be sure to provide the same level of respiratory compensation when setting the ventilator. 
  • Failing to provide a rate sufficient to compensate for the pre-intubation acidosis leads to a rapid drop in pH, bradycardia and eventually asystole.
  • In general, rates can be increased to about 30-35 breaths per minute, after which auto-PEEP becomes problematic.

Show References



Acute renal failure occurs in 1-25% of critically ill patients, with an associated mortality of 28 - 90%. 

The RIFLE Criteria represent the first consensus definition of acute renal failure used to classify critically ill patients as to their kidney function.  Notably, we use the worst possible classification according to the criteria, which measures either serum creatinine, urine output or both. 

Show References


Attachments

1006221408_RIFLE.jpg.doc (103 Kb)



Category: Critical Care

Title: Hypotension and MV

Posted: 6/15/2010 by Mike Winters, MD (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

Hypotension after intubation and initiation of mechanical ventilation

  • Approximately 25-30% of patients develop hypotension after intubation and initiation of mechanical ventilation (MV).
  • Although the literature is not robust, risk factors for hypotension after initiation of MV include:
    • hypotension prior to intubation
    • tachycardia prior to intubation
    • obesity
    • high intrathoracic pressure (COPD)
    • excess catecholamine states (ETOH withdrawal, cocaine intoxication) with rapid relaxation during RSI
  • In addition to administering isotonic intravenous fluids (IVFs) while preparing for intubation, consider having a vasopressor medication, such as phenylephrine, available if IVFs alone prove insufficient at maintaining blood pressure.

Show References



Platelet Transfusions in the Critically Ill

  • Recommendations for the transfusion of platelets in the critically ill patient is primarily extrapolated from the oncology literature; literature that is predominantly observational and expert opinion.
  • Nevertheless, indications for the transfusion of platelets in a critically ill ED patient include:
    • active bleeding with a plt count < 50 x 109/L
    • plt count < 10 x 109/L (high risk of spontaneous bleeding)
    • prior to an invasive procedure when the plt count is < 50 x 109/L
  • Importantly, the decision to transfuse platelets should also take into account the clinical setting (ie. a uremic patient with active bleeding)

Show References



Neuroleptic malignant syndrome (NMS), which is similar in symptomatology to malignant hyperthermia (MH), is characterized by the following:
1) increased body temperature
2) muscle rigidity
3) altered mental status
4) autonomic instability
 
The difference between NMS and MH is the etiology.  NMS is caused by the following medications:
Antipsychotics (haldol, phenothiazines, clozapine, olanzapine, risperadone)
Antiemetics (metoclopramide, droperidol, prochlorperazine)
CNS stimulants (amphetamines, cocaine)
Other (lithium, TCA overdose)
 
NMS can also be cause by disconinuation of dopaminergic drugs (amantadine, bromocriptine, levodopa)
 
Symptoms can begin to appear 24 to 72 hours after the onset of drug therapy, and are usually gradual. 
 
Management includes checking CK level (>1000 distinguishes NMS from sepsis), immediate removal of the offending drug, and consideration of Dantrolene or Bromocriptine.

Show References



Postcardiac Arrest Syndrome: Controlled Reoxygenation

  • In previous pearls, Dr. Marcolini has highlighted the poscardiac arrest syndrome (PCAS), comprised of brain injury, myocardial dysfunction, systemic ischemia/reperfusion response, and persistent precipitating disease.
  • Not surprisingly, postcardiac arrest brain injury is a major cause of morbidity and mortality, accounting for > 60% of deaths in some studies.
  • In addition to therapeutic hypothermia, consider "controlled reoxygenation" in order to optimize neurologic outcome.
  • Animal data has demonstrated that too much oxygen may worsen neuronal damage during the initial resuscitation phase.
  • Take Home Points:
    • Use a minimum amount of FiO2 to maintain SpO2 of 94-96%
    • Avoid unnecessary arterial hyperoxia

Show References



Category: Critical Care

Title: PRBCs in Neurocritical Care

Posted: 5/11/2010 by Mike Winters, MD (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

PRBC Transfusions in Neurocritical Care

  • Historically, neurocritical care textbooks have favored a more liberal PRBC transfusion strategy, as the brain is very sensitive to decreases in oxygen delivery.
  • Despite these recommendations, limited studies have failed to show a mortality benefit to PRBC transfusion in critically ill patients with neurologic illness.
  • Postulated reasons for the lack of morbidity or mortality benefit center around the injured brain's response to attempts to increase oxygen delivery through transfusion.
    • TBI: PET studies have shown an overall lower level of metabolic activity along with a lower oxygen extraction and loss of autoregulation
    • SAH: transfusion may increase the risk of vasospasm in SAH and worsen flow
  • Although the evidence is not overwhelming, current recommendations from SCCM-Eastern Society for the Surgery of Trauma recommend a restrictive PRBC transfusion threshold (Hgb < 7 gm/dL) even in neurocritical care patients.

Show References



In the ICU, diabetes insipidus (DI) develops in patients with pituitary surgery, brain trauma, intracranial hypertension and brain death.  Criteria include the following:

  • urine output >200 ml/hr or 3 ml/kg/hr
  • urine osmolality <150 mOsm/kg
  • serum sodium>145 mEq/L
  • urine specific gravity<1.005

In the ICU, patients are typically unable to consume free water to compensate for urinary losses, and dehydration, hypotension and hypernatremia occur.  Clinical signs may not appear until sodium levels surpass 155-160 mEq/L or serum osmolality surpsses 330 mOsm/kg. 

Symptoms include confusion, lethargy, coma, seizures and cerebral shrinkage associated with subdural or intraparenchymal hemorrhage. 

Treatment includes

  • controlling polyuria with vasopressin (antidiuretic, vasoconstrictive effects) and desmopressin (DDAVP - antidiuretic effect)
  • calculate and replace free water loss
  • TBW deficit (L) = body weight (kg) x 0.6 x (Na-140)/Na
  • monitor and replace urine losses hourly (using gastric access if possible)
  • monitor serum sodium and adjust therapy every 4 hours closely monitor for hyperglycemia and treat to prevent osmotic diuresis due to glucosuria

Show References



PRBC Transfusion Threshold for Patients with Cardiac Disease

  • As previously discussed, the PRBC transfusion threshold for the general population of critically ill patients is a Hgb < 7 gm/dL.
  • Traditional teaching has been to maintain a Hgb > 10 gm/dL in patients with a history of CAD.
  • This threshold stems from a 1950s cohort of Jehovah's Witness patients, and several observational studies, that demonstrated increased perioperative mortality in patients whose Hgb was < 10 gm/dL.
  • Recent studies, however, have found that patients with a history of CAD tolerate lower Hgb levels without increases in morbidity or mortality.  In fact, current cardiovascular surgery guidelines favor a conservative Hgb threshold (7 gm/dL) for patients with CAD.
  • Importantly, the Hgb threshold of < 7 gm/dL for PRBC transfusion applies to patients with simply a history of CAD and not to patients with evidence of an acute coronary syndrome (STEMI, NSTEMI, unstable angina).  Guidelines continue to recommend a Hgb > 10 gm/dL for patients with ACS.

Show References



It is true, 1/3 of Americans are obese.  There is conflicting evidence regarding the mortality risk of obesity (defined as BMI>30 kg/m2) in critically ill patients. 

It has been shown that abdominal fat has greater consequences than peripheral obesity, and based on this, a recent study has utilized the sagittal abdominal diameter (SAD) in ICU patients to show that abdominal obesity (as differentiated from BMI) poses an independent risk of death.  The SAD detects visceral fat, which has been shown to have metabolic and immune health consequences, including the following:

-incidence and severity of certain infections is higher

-excess adipocytes are associated with elevated levels of proinflammatory factors that favor insulin resistance, diabetes, dyslipidemia and hypertension, all of which lead to microcirculatory dysfunction

-rates of required renal replacement therapy and abdominal compartment syndrome correlate to increased SAD

-there is also a trend toward a longer length of ventilator weaning

See you at the gym.

Show References



Category: Critical Care

Title: Type B Lactic Acidosis

Posted: 4/13/2010 by Mike Winters, MD (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

Type B Lactic Acidosis

  • In the critically ill, patients may often have elevated lactate levels without ongoing tissue hypoperfusion.
  • In these patients it is important to consider the causes of what is referred to as "Type B Lactic Acidosis".
  • Pertinent to critically ill ED patients, consider the following:
    • Type B1 - related to underlying disease
      • renal faiilure
      • hepatic failure
      • malignancy
      • HIV
    • Type B2 - effects of drugs/toxins
      • acetaminophen
      • alcohols
      • beta-adrenergic agents: epinephrine
      • cocaine, methamphetamine
      • propofol
      • salicylates
      • valproic acid
      • metformin
    • Type B3 - inborn errors of metabolism

Show References



Category: Critical Care

Title: Magnesium Balance

Posted: 4/6/2010 by Evadne Marcolini, MD (Updated: 3/28/2024)
Click here to contact Evadne Marcolini, MD

Magnesium depletion has been described as "the most underdiagnosed electrolyte abnormality in current medical practice"

Important for electrically excitable tissues and smooth muscle cells, Mg is mostly located in bone, muscle and soft tissue.  Because only 1% is located in blood, your patient can be Mg depleted with normal serum levels. 

65% of ICU patients are magnesium depleted (and may not be hypomagnesemic). Because labs are unreliable, consider predisposing causes, such as diuretics, antibiotics (aminoglycosides, amphotericin), digitalis, diarrhea, chronic alcohol abuse, diabetes and acute MI (80% of AMI patients will have magnesium depletion in the first 48 hours). 

Mg depletion is typically accompanied by depletion of other electrolytes (K, Phos, Ca), and can cause arrhythmias (especially torsades) and promote digitalis cardiotoxicity. 

Hypermagnesemia is less common, and can be caused by hemolysis, renal insufficiency, DKA, adrenal insufficiency and lithium toxicity.  Clinical findings include hyporeflexia, prolonged AV conduction, heart block and cardiac arrest.  Treatment includes fluid and furosemide, calcium gluconate and dialysis. 

Show References



Ventilator Pearls for H1N1 Influenza Virus

  • As the spring/summer travel season begins, it is predicted that we will see additional cases of H1N1
  • The most common presentation requiring ICU admission to date has been a viral pneumonitis
  • As highlighted in previous pearls, the hallmark of disease has been refractory hypoxemia requiring mechanical ventilation in about 85% of patients.
  • Current recommendations for H1N1 respiratory failure:
    • Consider early intubation
    • Noninvasive ventilation has been unsuccessful in most and should generally be avoided
    • Low tidal volume settings (6 ml/kg) with PEEP based on FiO2 to maintain SpO2 > 88% and plateau pressure < 35 cm H2O
    • Although there is no proven mortality benefit to rescue therapies such as recruitment maneuvers, neuromuscular blockade, and prone ventilation, these can be considered in discussion with your intensivist.

Show References



Catheter-related bloodstream infections occur in 3-8 percent of insertions, and are the highest cause of nosocomial bloodstream infections in the ICU. 

The most effective measures to prevent catheter-related infections are as follows:

Especially applicable to those of us placing these lines in the ED or in the ICU is the last recommendation, based on a prospective study from Greece

-adequate knowledge and use of care protocols

-qualified personnel involved in changing and care

-use of biomaterials that inhibit microorganism growth and adhesion

-good hand hygiene

-use of an alcoholic formulation of chlorhexidine for skin disinfection and manipulation of the vascular line

-preference for subclavian route for placement

-use of full barrier protection during placement

-removal of unnecessary catheters

-use of ultrasound for placement of central lines

Show References



Category: Critical Care

Title: Warfarin and ICH

Posted: 3/16/2010 by Mike Winters, MD (Updated: 3/28/2024)
Click here to contact Mike Winters, MD

Warfarin and ICH

  • Warfarin causes approximately 10-15% of all intracerebral hemorrhages (ICH)
  • Many warfarin-related ICHs occur with INRs in the therapeutic range
  • Patients with warfarin-related ICH have higher mortality and typically suffer worse neurologic outcome
  • The primary pitfall in treating patients with warfarin-related ICH is the failure to rapidly normalize the INR
  • Do not delay treatment while awaiting the results of coagulation labs
  • Patients should receive IV vitamin K via slow infusion and FFP
  • Prothrombin Complex Concentrate (PCC) is gaining popularity but much of the supporting literature uses agents not available in the US
  • Similarly, there is no significant evidence that recombinant factor VIIa improves outcomes in patients with warfarin-related ICH

Show References



Primary Intracranial hemorrhage is associated with the following risk factors:

  • hypertension, smoking, alcohol, hypocholesterolemia, genetic factors, warfarin, phenylpropylamine, cocaine and methamphetamine. 

Common causes of secondary ICH are as follows:

  • vascular malformations, arteriovenous malformations, cavernous angiomas, small arterial telangiectasia, and primary and secondary brain tumors.

The question of how to address elevated blood pressure in spontaneous intracranial hemorrhage has been debated.  High blood pressure may cause hematoma expansion, but this has not been proven.  Lowering blood pressure may help reduce neurologic deterioration, but this has also not been proven in the literature. 

The AHA recommended guidelines for blood pressure management in spontaneous ICH are as follows:

If SBP>200 or MAP>150, consider aggressive reduction of BP with continuous IV infusion, monitoring BP every 5 minutes

If SBP>180 or MAP>130, with evidence or suspicion of elevated ICP, consider monitoring ICP and reducing BP using intermittent or continuous IV medications to keep CPP>60 to 80

If SBP>180 or MAP>130 without evidence or suspicion of elevated ICP, then consider a modest reduction of BP (MAP of 110 or targeted SBP 160/90) using intermittent or continuous IV medications, monitoring BP every 15 minutes

Show References